Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (stimulated, ml/min) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Adverse events · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) led to lower xerostomia (grade >= 2, 0-4 scale) compared with amifostine (subcutaneous); GRADE not reported.
2 findings from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Xerostomia (grade >= 2, 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to lower xerostomia (grade >= 2, 0-3 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in salivary flow rate (stimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes overall survival compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival (locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Adverse events · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Vaginal delivery not achieved within 24 hours · patients with induction of labour at term
1 finding from 1 review
Uterine hyperstimulation with fetal heart rate changes · women requiring induction of labour
Intracervical PGE₂ showed no clear difference in uterine hyperstimulation (with fetal heart rate changes) compared with placebo (low certainty).
1 finding from 1 review
Caesarean section · women requiring induction of labour
Intracervical PGE₂ showed no clear difference in caesarean section compared with placebo (moderate certainty).
1 finding from 1 review
Neonatal death or serious neonatal perinatal morbidity · women requiring induction of labour
1 finding from 1 review
Serious maternal morbidity or death · women requiring induction of labour
1 finding from 1 review
Admission to neonatal intensive care unit · women requiring induction of labour
Intracervical PGE₂ showed no clear difference in neonatal intensive care unit admission compared with placebo (low certainty).
1 finding from 1 review